The advisor is set up to meet the CDC.
According to a document released on April 14, advisors from the Centers for Disease Control and Prevention are considering advisers to narrow down the general use of the Covid-19 vaccine.
Most experts in the Vaccination Practices Advisory Committee (ACIP) subgroup, which advises the CDC on vaccines, have determined that the Covid-19 vaccine should not be universally recommended, the document says.
76% of the subgroup advisors studying the issue said they supported the non-university recommendations as of April 3.
That will increase from 67% in February.
The advisor said he was satisfied with non-universal recommendations, such as recommending vaccines only for certain age groups.
Related Stories
ACIP simply provides advice to the CDC, but agents usually turn advice into official recommendations.
According to the CDC, a formal ACIP vote on CDC advice in the next round of the Covid-19 vaccine or the next round of the 2025-2026 vaccine is not expected to take place until June.
According to the presentation, post-presentation discussions will look into whether there are groups that “not clearly recommend vaccination with the 2025-2026 vaccine.” The advisors were also trying to debate whether unintended consequences were potential if recommendations were narrowed.
Ruthlingel, which will be offering that presentation, concluded that the vaccine “provided additional protection against Covid-19-related emergency departments and emergency care visits and hospitalizations compared to doses of the 2024-2025 vaccine.”
High levels of existing immunity after Covid-19 infection may have an impact on efficacy outcomes, Link-Gelles writes. Previous infections “contribute to protection against future illnesses, but protection fades over time,” she said.
According to the CDC, about 22% of US adults received one of the 2024-2025 Covid-19 vaccines in late March 2025, compared to 21% who received the available vaccines between 2023-late 2024 and late March 2024.
